Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad26.RSV.preF + RSV preF protein
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
Ad26.RSV.preF + RSV preF protein is a combination vaccine developed for the prevention of respiratory syncytial virus (RSV) infection, particularly in older adults. The vaccine consists of two components: a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a prefusion conformation-stabilized RSV fusion (preF) protein, and recombinant RSV preF protein. This combination is designed to induce robust humoral and cellular immune responses by presenting the immune system with both vector-expressed and directly administered prefusion F antigen. Clinical studies have demonstrated that this vaccine regimen provides high protective efficacy against lower respiratory tract disease caused by RSV in adults aged 60 years or older[1][2][3][4][5][6]. The addition of the recombinant RSV preF protein enhances immunogenicity compared to either component alone[2]. Janssen, part of Johnson & Johnson, is the primary developer.
- Other names
- Ad26.RSV.preF-RSV preF protein vaccineAd-26.RSV.preF-RSV preF protein vaccineAd 26.RSV.preF-RSV preF protein vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on Ad26.RSV.preF + RSV preF protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad26.RSV.preF + RSV preF protein.